Ameriprise’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-68,986
| Closed | -$15.2M | – | 4087 |
|
|
2025
Q4 | $15.2M | Buy |
68,986
+10,500
| +18% | +$1.7M | ﹤0.01% | 1608 |
|
|
2025
Q3 | $5.6M | Buy |
58,486
+12,437
| +27% | +$794K | ﹤0.01% | 2357 |
|
|
2025
Q2 | $2.24M | Buy |
+46,049
| New | +$1.11M | ﹤0.01% | 2887 |
|
|
2021
Q2 | – | Sell |
-964
| Closed | -$51K | – | 3899 |
|
|
2021
Q1 | $51K | Buy |
+964
| New | +$47.6K | ﹤0.01% | 3799 |
|
|
2020
Q1 | – | Sell |
-607
| Closed | -$47K | – | 3654 |
|
|
2019
Q4 | $47K | Buy |
+607
| New | +$27.8K | ﹤0.01% | 3678 |
|
|
2019
Q1 | – | Sell |
-599
| Closed | -$28K | – | 3704 |
|
|
2018
Q4 | $28K | Hold |
599
| – | – | ﹤0.01% | 3586 |
|
|
2018
Q3 | $53K | Hold |
599
| – | – | ﹤0.01% | 3656 |
|
|
2018
Q2 | $62K | Hold |
599
| – | – | ﹤0.01% | 3594 |
|
|
2018
Q1 | $48K | Hold |
599
| – | – | ﹤0.01% | 3588 |
|
|
2017
Q4 | $81K | Hold |
599
| – | – | ﹤0.01% | 3569 |
|
|
2017
Q3 | $97K | Hold |
599
| – | – | ﹤0.01% | 3602 |
|
|
2017
Q2 | $90K | Buy |
+599
| New | +$82.8K | ﹤0.01% | 3660 |
|
Ameriprise's CDTX Position: Q1 2026 in Review
Ameriprise sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 68,986 shares — an estimated $15.2M sold.
Ameriprise first reported a position in CDTX in Q2 2017 and held it in 12 quarters. The position peaked at $15.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Ameriprise reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Ameriprise sold 68,986 Cidara Therapeutics shares in Q1 2026, an estimated $15.2M.
- Ameriprise first reported a position in Cidara Therapeutics in Q2 2017 and held it in 12 quarters.
- Ameriprise's Cidara Therapeutics position peaked at $15.2M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.